Gilead develops solid tumour cell therapy with Gadeta
CAR T, Gadeta, Gilead, Kite, R&D, TCRs
0 Comment
Gilead has option to buy biotech if things go well
Gilead
Gilead takes ‘HIV eradication’ combo into clinic
Gilead, hepatitis C, HIV, infectious diseases
0 Comment
New approach tackles reserve of HIV within the body
US judge overturns Gilead $2.54bn patent infringement ruling
Gilead, Hepatitis, litigation, Merck & Co, patent
0 Comment
Federal judge throws out Merck’s patent claim against Gilead
Cellectis confident on ‘off the shelf’ CAR-Ts despite setbacks
blood cancer, cancer, CAR T, Cellectis, Gilead, Novartis, Pfizer
0 Comment
US hospitals struggle to provide approved autologous therapies
Kymriah gets fast DLBCL review in US and Europe
cancer, CAR T, Gilead, Novartis
0 Comment
Fast reviews set up showdown with Gilead
Gilead goes full throttle on CAR-Ts with $567m acquisition
ASH17, cancer, CAR T, Gilead, Novartis
0 Comment
Gilead hopes CDL technology will create therapies targeting solid tumours
GSK’s newly approved HIV treatment Juluca expected to dominate
FDA approvals 2017, Gilead, GlaxoSmithKline, HIV, infectious diseases
0 Comment
Gilead gains CAR-T approval, undercuts rival’s headline price
blood cancer, cancer, CAR T, cell and gene therapy, Gilead, Novartis
0 Comment
Cancer cell therapy approved for aggressive blood cancer
